Eric I. Richman is Director at PHARMATHENE, INC (PIP). They have made 14 open-market trades across 4 companies since 2010, most recently 2026-10-01.
CIK 0001326190
11 open-market purchases totalling $298K since 2010, against 3 sales. Across 11 scored buys the stock is up 7.4% at ninety days, and 4.0 points ahead of the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 64% | 27% | 45% |
| Avg Move | +4.5% | +5.3% | +7.4% |
| Alpha | +5.2% | +4.4% | +4.0% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GANX | BUY | 2024-07-01 | 2024-07-01 | $1.22 | $21K | +15.0% | -10.0% | +48.3% |
| GANX | BUY | 2022-05-25 | 2022-05-27 | $2.58 | $6K | +28.2% | +42.9% | +19.7% |
| GANX | BUY | 2022-05-19 | 2022-05-23 | $2.79 | $37K | +23.7% | +29.3% | +14.8% |
| NBSE | BUY | 2022-03-01 | 2022-03-07 | $1.64 | $6K | +22.5% | +31.0% | -29.6% |
| NBSE | BUY | 2021-04-26 | 2021-04-27 | $5.00 | $25K | -11.9% | -11.2% | -37.3% |
| NBSE | BUY | 2020-04-30 | 2020-05-04 | $6.00 | $65K | +1.0% | -2.8% | -4.7% |
| ADMA | BUY | 2018-06-08 | 2018-06-11 | $4.78 | $25K | +3.6% | -6.2% | +38.2% |
| ADMA | BUY | 2017-11-09 | 2017-11-13 | $2.15 | $54K | +12.7% | -10.6% | +35.3% |
| PIP | SELL | 2016-04-13 | 2016-04-15 | $2.20 | $200K | +5.2% | -0.9% | +9.1% |
| PIP | SELL | 2016-04-13 | 2016-04-15 | $2.20 | $725K | +5.2% | -0.9% | +9.1% |
| PIP | SELL | 2016-04-07 | 2016-04-11 | $2.20 | $26K | +11.1% | +8.3% | +16.1% |
| ADMA | BUY | 2015-03-13 | 2015-03-17 | $7.88 | $28K | -20.4% | -1.5% | -1.5% |
| PIP | BUY | 2011-11-10 | 2011-11-14 | $1.50 | $15K | -12.4% | -1.1% | -1.1% |
| PIP | BUY | 2010-06-17 | 2010-06-21 | $1.58 | $16K | -12.4% | -1.1% | -1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.